In This Article:
Cogstate (ASX:CGS) Full Year 2024 Results
Key Financial Results
-
Revenue: US$43.4m (up 7.4% from FY 2023).
-
Net income: US$5.45m (up 53% from FY 2023).
-
Profit margin: 13% (up from 8.8% in FY 2023). The increase in margin was driven by higher revenue.
-
EPS: US$0.032 (up from US$0.021 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Cogstate EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 54%.
The primary driver behind last 12 months revenue was the Clinical Trials (incl. Precision Recruitment Tool & Research) segment contributing a total revenue of US$39.4m (91% of total revenue). The largest operating expense was General & Administrative costs, amounting to US$15.7m (83% of total expenses). Explore how CGS's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Healthcare Services industry in Australia.
Performance of the Australian Healthcare Services industry.
The company's shares are down 8.2% from a week ago.
Balance Sheet Analysis
Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We've done some analysis and you can see our take on Cogstate's balance sheet.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.